Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Lapses at the new England journal of medicine.

× No keyword cloud information.

12 in total

Review 1. The coxibs, selective inhibitors of cyclooxygenase-2.

Authors: G A FitzGerald; C Patrono
Journal: N Engl J Med Date: 2001-08-09 Impact factor: 91.245

2. Commercial influence and the content of medical journals.

Authors: Joel Lexchin; Donald W Light
Journal: BMJ Date: 2006-06-17

3. How the New England Journal missed warning signs on Vioxx: medical weekly waited years to report flaws in article that praised pain drug; Merck seen as "punching bag".

Authors: David Armstrong
Journal: Wall St J (East Ed) Date: 2006-05-15

4. Expression of concern reaffirmed.

Authors: Gregory D Curfman; Stephen Morrissey; Jeffrey M Drazen
Journal: N Engl J Med Date: 2006-02-22 Impact factor: 91.245

5. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial.

Authors: Robert S Bresalier; Robert S Sandler; Hui Quan; James A Bolognese; Bettina Oxenius; Kevin Horgan; Christopher Lines; Robert Riddell; Dion Morton; Angel Lanas; Marvin A Konstam; John A Baron
Journal: N Engl J Med Date: 2005-02-15 Impact factor: 91.245

Review 6. Risk of cardiovascular events associated with selective COX-2 inhibitors.

Authors: D Mukherjee; S E Nissen; E J Topol
Journal: JAMA Date: 2001 Aug 22-29 Impact factor: 56.272

7. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group.

Authors: C Bombardier; L Laine; A Reicin; D Shapiro; R Burgos-Vargas; B Davis; R Day; M B Ferraz; C J Hawkey; M C Hochberg; T K Kvien; T J Schnitzer
Journal: N Engl J Med Date: 2000-11-23 Impact factor: 91.245

4. Conflicts of interest at medical journals: the influence of industry-supported randomised trials on journal impact factors and revenue - cohort study.

Authors: Andreas Lundh; Marija Barbateskovic; Asbjørn Hróbjartsson; Peter C Gøtzsche
Journal: PLoS Med Date: 2010-10-26 Impact factor: 11.069

Lapses at the new England journal of medicine.

Review 1. The coxibs, selective inhibitors of cyclooxygenase-2.

2. Commercial influence and the content of medical journals.

3. How the New England Journal missed warning signs on Vioxx: medical weekly waited years to report flaws in article that praised pain drug; Merck seen as "punching bag".

4. Expression of concern reaffirmed.

5. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial.

Review 6. Risk of cardiovascular events associated with selective COX-2 inhibitors.

7. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group.

Review 8. Peer review: a flawed process at the heart of science and journals.

9. Patient safety requires a new way to publish clinical trials.

10. Medical journals are an extension of the marketing arm of pharmaceutical companies.

1. Clinical studies in medical journals.

2. Should medical journals carry drug advertising? Yes.

3. Medical discovery in the age of breaking news.

4. Conflicts of interest at medical journals: the influence of industry-supported randomised trials on journal impact factors and revenue - cohort study.

5. Human Embryonic Stem Cell Research, Abortion, and Publication Bias in the New England Journal of Medicine.

6. Response to 'Lapses at the NEJM'.

7. Biomedical research and corporate interests: a question of academic freedom.

8. Legal remedies for medical ghostwriting: imposing fraud liability on guest authors of ghostwritten articles.